Evaluate the efficacy and safety of vorolanib combined with cadonilimab in the treatment of untreated advanced RCC patients.
Subjects voluntarily participate in this study, willing and able to comply with and sign the informed consent form;
Histologically confirmed clear cell renal cell carcinoma;
Advanced (not suitable for curative surgery or radiation therapy) or metastatic (AJCC Stage IV) RCC;
Confirmed to have at least one measurable lesion according to RECIST 1.1 criteria;
Received any systemic treatment for RCC, unless the investigator can provide evidence that the subject has been randomly assigned to the placebo group;
Central nervous system metastasis;
Active malignant tumor in the past 24 months (except for renal cell carcinoma, skin basal cell carcinoma or squamous cell carcinoma that has been clearly treated, as well as cervical or bladder carcinoma in situ). Participants with a history of localized and low-risk prostate cancer who have received curative treatment and have not had a prostate-specific antigen (PSA) recurrence in the past 5 years may participate in the study;
Received prior radiotherapy within 21 days before the start of study treatment (palliative radiotherapy for bone lesions is allowed, provided it is completed at least 2 weeks before the start of study treatment);